Currentcare_continuumPolicy n05189

Skin Substitutes and Other Advanced Wound Healing Products

Customize your policy alerts

Sign up for care_continuum Policy n05189 alerts

Get alerted when Policy n05189 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical coverage and medical necessity criteria for use of biologic and bioengineered skin substitutes and related advanced wound healing products for Network Health members, including indications, limits on applications, and documentation expectations.

Policy Summary

Payercare_continuum

PolicySkin Substitutes and Other Advanced Wound Healing Products

Policy CodePolicy n05189

Change TypeNo material changes

Effective Date

Last ReviewFeb 19, 2026

Next Review DateFeb 20, 2027

Key ActionObtain prior authorization and submit clinical documentation showing wound size, prior conventional therapies and duration, debridement status, vascular assessment (ABI/TBI or palpable pulses), and evidence of improvement for additional applications.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentcare_continuumPolicy n05189

Skin Substitutes and Other Advanced Wound Healing Products

Customize your policy alerts

Sign up for care_continuum Policy n05189 alerts

Get alerted when Policy n05189 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payercare_continuum

PolicySkin Substitutes and Other Advanced Wound Healing Products

Policy CodePolicy n05189

Change TypeNo material changes

Effective Date

Last ReviewFeb 19, 2026

Next Review DateFeb 20, 2027

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2initial approved applications

12wmax treatment duration (chronic)

8max applications per episode

>=0.70ABI threshold

>=1.0 cm2min ulcer size

Medical Necessity and Coverage Criteria

Breast Reconstruction

Covered when ANY of the following are met for breast reconstruction:

Breast reconstruction: Skin substitute is medically necessary when (i) there is insufficient tissue expander or implant coverage by the pectoralis major muscle requiring additional coverage OR (ii) there are viable but compromised or thin postmastectomy skin flaps that are at risk of dehiscence or necrosis OR (iii) the infra-mammary fold and lateral mammary folds have been undermined during mastectomy and reestablishment of these landmarks are needed

Non-healing surgical/traumatic/radiation wounds

Covered when ALL of the following are met:

Non-healing surgical/traumatic/radiation wounds: (i) Used in conjunction with standard wound care regimens to promote wound healing AND (ii) ulcer or skin deficit is at least 1.0 square cm in size AND (iii) has failed or had no response to documented conventional wound therapies for at least 6 weekssize >= 1.0 sq cm; duration >= 6 weeks

Up to 2 initial applications; additional applications only with documented improvement

Full/Partial Thickness and Diabetic Foot Ulcers

Covered when ALL of the following are met:

Full/partial thickness and diabetic foot ulcers: (i) Used in conjunction with standard wound care regimens to promote wound healing AND (ii) ulcer or skin deficit is at least 1.0 square cm in size AND (iii) has failed or had no response to documented conventional wound therapies for at least 12 weeks AND (iv) the involved foot has adequate blood supply (ABI >= 0.70 or positive palpable pedal pulse); for diabetic foot ulcers also: diagnosis of type I or II diabetes and optimal diabetic management during treatmentsize >= 1.0 sq cm; duration >= 12 weeks; ABI >= 0.70

Limited to 2 initial applications; additional applications require documented improvement; applications beyond 12 weeks are not medically necessary

Venous Insufficiency / Venous Stasis Ulcers

Covered when ALL of the following are met:

Venous stasis ulcers: (i) The venous stasis ulcer has failed or had no response to documented conventional wound therapies for at least 12 weeks AND (ii) if the wound is on the foot, the involved foot has adequate blood supply (ABI >= 0.70 or palpable pedal pulse) AND (iii) the venous stasis ulcer history is longer than 4 weeks duration AND (iv) the patient is following appropriate compression therapy with documented diligent use (multilayer dressings, compression hose, or pneumatic compression)duration >= 12 weeks; ABI >= 0.70; history > 4 weeks

Limited to 2 initial applications; additional applications only with documented improvement

General prerequisites and limits

For all wound types treated with skin substitute grafts ALL of the following must be met:

General prerequisites: (a) Ulcer must be clean, free of infection and exudate and have undergone debridement to remove necrotic debris AND (b) any underlying infection (cellulitis, osteomyelitis) must be resolved prior to initiation of any skin substitute regimen AND (c) limited to two (2) initial applications when criteria are met AND (d) additional applications may be applied only with evidence of improvement (e.g., granulation, reduction in size of ulcer) AND (e) application use beyond 12 weeks is considered not medically necessary

Documentation of response at least once every 30 days is expected

Burns

Covered skin substitutes for burns are specified by product and burn depth:

Burns: Certain listed products are considered medically necessary for burn care per product-specific indications: Biobrane (Q4100) for temporary covering of full thickness or superficial partial-thickness burns and Biobrane L; TransCyte (Q4182) and other listed products as indicated by HCPCS codes and the product table in the policysee code group for product-specific indications

See CPT/HCPCS code group for product-to-code mapping and burn-depth indications

Skin substitutes are not medically necessary for pressure ulcers. Requests for skin substitute use for indications other than those explicitly listed in this policy will be reviewed under the plan’s experimental/investigational/unproven process and are subject to denial.

Skin substitute grafts are contraindicated and considered NOT medically necessary in patients with inadequate control of underlying conditions or exacerbating factors (for example, uncontrolled diabetes or active infection). These underlying issues must be addressed and stabilized prior to consideration of skin substitute therapy.

Repeat or alternative applications of another skin substitute graft following a previous full course that was unsuccessful are not considered medically reasonable and necessary and therefore are not covered.

Re-treatment with any skin substitute for a diabetic foot ulcer or venous stasis ulcer within one (1) year after a prior full course is considered treatment failure and is not medically necessary.

Treatment with skin substitutes for any chronic skin wound for greater than twelve (12) weeks is considered not medically necessary.

Coding, Thresholds, and Measurement Requirements

Covered HCPCS/Q-codesHCPCSCovered

Q4101	Apligraf
Q4102	Oasis Wound Matrix, per sq cm
Q4106	Dermagraft
Q4110	Primatrix, per sq cm
Q4116	Alloderm, per square cm
Q4121	TheraSkin
Q4122	DermACELL, per sq cm
Q4124	OASIS ultra tri-layer wound matrix, per sq cm
Q4128	FlexHD or AllopatchHD, per sq cm
Q4132	Grafix Core, per sq cm

1–10 of 17

1/2

Ulcer or skin deficit size — minimum size where required

Minimum wound size>= 1.0 square cm

Applies toNon-healing surgical/traumatic/radiation wounds; full/partial thickness and diabetic foot ulcers; many other indications per criteria sets

Documentation requirementWound size must be recorded in clinical documentation prior to approval

Diabetic foot ulcer failure of conventional therapy duration

Required failure duration>= 12 weeks

Applicable indicationsFull/partial-thickness ulcers and diabetic foot ulcers

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior authorization required for listed Q‑codes

Prior authorization is required for skin substitute products and will be evaluated against the medical necessity criteria. The policy lists covered HCPCS/Q‑codes (e.g., Q4101, Q4102, Q4106, Q4110, Q4116, Q4121, Q4122, Q4124, Q4128, Q4132, Q4133, Q4151, Q4159, Q4186, Q4187, Q4100, Q4182) which must be used when requesting authorization.

Authorization decisions are based on the medical necessity criteria in the policy.
Covered Q‑codes are listed in the policy and must be used for requests.

Step Therapy

Conservative therapy requirement (documented failure durations)

Documented failure or lack of response to conventional wound therapies for the specified duration is required before skin substitute approval: at least 6 weeks for non‑healing surgical/traumatic/radiation wounds and at least 12 weeks for full/partial‑thickness and diabetic foot ulcers (and venous stasis ulcers).

Background and Scope

Biologic and bioengineered skin substitutes include several product types used to support wound healing by providing a scaffold or biologic components; common categories are acellular matrices (scaffolds derived from xenogeneic collagen or tissue without viable cells), allogenic matrices (derived from human tissues and containing regenerative components), composite matrices (human cells combined with collagen or synthetic supports), and human skin allografts. These products are regulated by the FDA and identified in this policy by specific HCPCS/Q‑codes for covered indications.

Product Type Definitions

Acellular matrices — definition and role

DefinitionAcellular matrices are derived from xenogeneic collagen or tissue and provide a scaffold to promote healing without viable cells.

Primary roleProvide structural scaffold to support cellular ingrowth and accelerate wound closure

Typical compositionAllogenic or xenogeneic collagen, membrane or cellular remnants; majority of bioengineered skin substitutes

Clinical contextUsed with standard wound care regimens to promote wound healing when medical necessity criteria are met

Allogenic matrices — definition and role

DefinitionAllogenic matrices are derived from human tissues (often neonatal foreskin) containing regenerative components for soft tissue support and at times full-thickness skin loss.

Policy Summary

Payercare_continuum

PolicySkin Substitutes and Other Advanced Wound Healing Products

Policy CodePolicy n05189

Change TypeNo material changes

Effective Date

Last ReviewFeb 19, 2026

Next Review DateFeb 20, 2027

SourceLink

On This Page

Additional requirements

Also requires adequate blood supply (ABI >= 0.70 or palpable pedal pulse) and documented optimal diabetic management for diabetic foot ulcers

Non-healing surgical/traumatic/radiation wound failure duration

Required failure duration>= 6 weeks

Applicable indicationsNon-healing surgical, traumatic, and/or radiation therapy wounds

Use contextMust be used in conjunction with standard wound care regimens to promote healing

Ankle-Brachial Index (ABI) — adequate blood supply threshold for foot wounds

ABI threshold>= 0.70 or palpable pedal pulse

Applies toInvolved foot for diabetic foot ulcers and foot wounds in venous stasis ulcer criteria

DocumentationVascular assessment (ABI) or palpable pedal pulses must be recorded prior to initiation

Toe-Brachial Index (TBI) — threshold

TBI threshold>= 0.50 or palpable pedal pulse

Specific toToe-Brachial Index requirement for diabetic foot ulcers per policy

DocumentationRecord TBI or palpable pedal pulses as part of vascular assessment prior to treatment

Non‑healing surgical/traumatic/radiation wounds: failed/no response to conventional therapies for ≥ 6 weeks.

Full/partial thickness, diabetic foot and venous stasis ulcers: failed/no response to conventional therapies for ≥ 12 weeks.

Documentation Required

Required clinical documentation (wound size, prior therapies and clinical data)

Clinical documentation must demonstrate wound characteristics and prior management: wound size (≥ 1.0 sq cm where required), prior conventional wound therapies and their durations (e.g., ≥6 or ≥12 weeks per indication), debridement status, resolution of infection, vascular assessment (ABI/TBI or palpable pulses), and diabetes control when applicable.

Wound size: at least 1.0 square cm when required by the indication.
Document prior therapies and duration (e.g., ≥6 or ≥12 weeks as applicable).
Document debridement, absence/resolution of infection, ABI/TBI or palpable pedal pulses, and diabetic management for diabetic foot ulcers.

Documentation Required

Ongoing documentation frequency — document response every 30 days

Response to treatment must be documented in the medical record at least once every 30 days for each episode of wound treatment.

Documentation of improvement is required for approval of additional applications (e.g., granulation or reduction in size).

Denial Risk

Unlisted or unspecified codes may be denied as experimental

Requests submitted using unlisted codes or codes not included in the policy will be considered experimental, investigational, or unproven and may be denied.

Network Health will consider requests using an unlisted code to be experimental/investigational/unproven.
Codes not listed in the policy will be treated as experimental/investigational.

Denial Risk

Re‑treatment and prolonged therapy are not medically necessary

Re‑treatment within one year after a prior full course for a diabetic foot ulcer or venous stasis ulcer is considered treatment failure and is not medically necessary; treatments beyond 12 weeks for any chronic skin wound are also not medically necessary.

Repeat or alternative applications after a previous full course that was unsuccessful are not considered medically reasonable and necessary.
Application use beyond 12 weeks is considered not medically necessary.

Primary roleProvide human-derived regenerative components (fibroblasts, membrane) to support soft tissue repair

Typical sourceHuman neonatal foreskin tissue processed for clinical use

Composite matrices — definition and role

DefinitionComposite matrices combine human keratinocytes/fibroblasts with xenogeneic collagen or synthetic supports; commonly called human skin equivalents.

Primary roleContain active cellular components producing proteins and bioactive compounds to accelerate healing

Typical structureHuman cells supported by synthetic mesh or xenogeneic collagen

Human skin allografts — definition and role

DefinitionHuman skin allografts are donated human skin/cadaver tissue processed to remove cells to avoid immunologic rejection.

Primary roleProvide biologic dermal matrix from human donor tissue for temporary or definitive wound coverage

Processing noteIntact cells are treated and removed to reduce immunologic rejection prior to clinical use